[go: up one dir, main page]

MX2022010657A - Anticuerpos conjugados con moleculas de acidos grasos y usos de los mismos. - Google Patents

Anticuerpos conjugados con moleculas de acidos grasos y usos de los mismos.

Info

Publication number
MX2022010657A
MX2022010657A MX2022010657A MX2022010657A MX2022010657A MX 2022010657 A MX2022010657 A MX 2022010657A MX 2022010657 A MX2022010657 A MX 2022010657A MX 2022010657 A MX2022010657 A MX 2022010657A MX 2022010657 A MX2022010657 A MX 2022010657A
Authority
MX
Mexico
Prior art keywords
antibodies
fatty acid
acid molecules
antibodies conjugated
bsabs
Prior art date
Application number
MX2022010657A
Other languages
English (en)
Inventor
Minghan Wang
Hui Zou
Haiqun Jia
Jack Chongyang Li
Original Assignee
Phanes Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Phanes Therapeutics Inc filed Critical Phanes Therapeutics Inc
Publication of MX2022010657A publication Critical patent/MX2022010657A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Fats And Perfumes (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se describen anticuerpos monoclonales (mAbs) o anticuerpos biespecíficos (bsAbs) o anticuerpos multi-específicos que comprenden una molécula de ácido graso (FA) conjugada con o cerca del dominio de unión a antígeno; se describen también ácidos nucleicos que codifican para los anticuerpos, composiciones que comprenden los anticuerpos, y métodos para producir los anticuerpos y el uso de los anticuerpos para tratar o prevenir enfermedades, tales como el cáncer y/o sus complicaciones asociadas.
MX2022010657A 2020-02-27 2021-02-25 Anticuerpos conjugados con moleculas de acidos grasos y usos de los mismos. MX2022010657A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202062982476P 2020-02-27 2020-02-27
PCT/US2021/019583 WO2021173783A1 (en) 2020-02-27 2021-02-25 Antibodies conjugated with fatty acid molecules and uses thereof

Publications (1)

Publication Number Publication Date
MX2022010657A true MX2022010657A (es) 2022-09-23

Family

ID=77490164

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022010657A MX2022010657A (es) 2020-02-27 2021-02-25 Anticuerpos conjugados con moleculas de acidos grasos y usos de los mismos.

Country Status (11)

Country Link
US (1) US20230089926A1 (es)
EP (1) EP4110398A4 (es)
JP (1) JP2023515196A (es)
KR (1) KR20220145854A (es)
CN (1) CN115279412A (es)
AU (1) AU2021226336A1 (es)
BR (1) BR112022013575A2 (es)
CA (1) CA3164646A1 (es)
IL (1) IL295413A (es)
MX (1) MX2022010657A (es)
WO (1) WO2021173783A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112021022682A2 (pt) 2019-05-14 2022-02-22 Provention Bio Inc Métodos e composições para prevenir diabetes do tipo 1
CA3182445A1 (en) 2020-06-11 2021-12-16 Francisco Leon Methods and compositions for preventing type 1 diabetes
KR20240004937A (ko) 2021-05-05 2024-01-11 이매틱스 바이오테크놀로지스 게엠베하 Bma031 항원 결합 폴리펩타이드

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060099208A1 (en) * 2004-11-08 2006-05-11 Undurti Das N Method of potentiating the therapeutic action of monoclonal and polyclonal antibodies
WO2011028952A1 (en) * 2009-09-02 2011-03-10 Xencor, Inc. Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
AU2011275749C1 (en) * 2010-07-09 2015-09-17 Aduro Biotech Holdings, Europe B.V. Agonistic antibody to CD27
EP2590999A1 (en) * 2010-07-09 2013-05-15 Jv Bio Srl Lipid-conjugated antibodies
WO2013192546A1 (en) * 2012-06-22 2013-12-27 Cytomx Therapeutics, Inc. Activatable antibodies having non-binding steric moieties and mehtods of using the same
IN2015DN00552A (es) * 2012-07-19 2015-06-26 Redwood Bioscience Inc
US20140363493A1 (en) * 2013-06-10 2014-12-11 Albert Einstein College Of Medicine Of Yeshiva University LIPID NANOPARTICLES FOR TARGETED siRNA DELIVERY
AU2014287011A1 (en) * 2013-07-12 2016-02-25 Zymeworks Inc. Bispecific CD3 and CD19 antigen binding constructs
EP3892294A1 (en) * 2013-08-28 2021-10-13 AbbVie Stemcentrx LLC Site-specific antibody conjugation methods and compositions
CN108137706A (zh) * 2015-07-15 2018-06-08 酵活有限公司 药物缀合的双特异性抗原结合构建体
CN109498817A (zh) * 2017-09-14 2019-03-22 上海交通大学 一种多细胞靶向脂质体
WO2019222282A1 (en) * 2018-05-14 2019-11-21 Harpoon Therapeutics, Inc. Conditionally activated binding protein comprising a sterically occluded target binding domain
BR112020023330A2 (pt) * 2018-05-14 2021-04-20 Harpoon Therapeutics, Inc. porção de ligação para ativação condicional de moléculas de imunoglobulina

Also Published As

Publication number Publication date
WO2021173783A1 (en) 2021-09-02
EP4110398A1 (en) 2023-01-04
KR20220145854A (ko) 2022-10-31
US20230089926A1 (en) 2023-03-23
IL295413A (en) 2022-10-01
CA3164646A1 (en) 2021-09-02
AU2021226336A1 (en) 2022-08-11
EP4110398A4 (en) 2024-07-10
JP2023515196A (ja) 2023-04-12
CN115279412A (zh) 2022-11-01
BR112022013575A2 (pt) 2022-09-13

Similar Documents

Publication Publication Date Title
PH12020552010A1 (en) Anti-cd33 antibodies, anti-cd33/anti-cd3 bispecific antibodies and uses thereof
MX2022010657A (es) Anticuerpos conjugados con moleculas de acidos grasos y usos de los mismos.
CL2023002690A1 (es) Anticuerpos anti-muc16-cd3 biespecíficos y conjugados anti-muc16-fármacos (divisional de 202102645)
MY198034A (en) Tumor-targeted agonistic cd28 antigen binding molecules
PE20211217A1 (es) Anticuerpos estabilizadores de trem2
PE20221262A1 (es) Anticuerpos terapeuticos y sus usos
PE20220392A1 (es) Moleculas de union a claudina-6 y usos de las mismas
AR123480A1 (es) Moléculas de unión terapéuticas
AR100573A1 (es) Anticuerpos anti-il-17, un método para producirlos y utilizarlos
RU2016115866A (ru) Мультиспецифические антитела с обменянными доменами и одинаковыми вариабельными доменами легкой цепи
PE20121542A1 (es) Moleculas de anticuerpo anti-gcc y composiciones y metodos relacionados
PE20181082A1 (es) Constructos de anticuerpos para flt3 y cd3
IL273841B1 (en) Antibodies targeting cd137 and methods of use thereof
PE20230444A1 (es) Anticuerpos
AR127271A1 (es) Anticuerpos biespecíficos que se unen específicamente a cd47 y cd20, y usos de los mismos
ZA202304787B (en) Anti-betacellulin antibodies, fragments thereof, and multi-specific binding molecules
MX2021009533A (es) Composiciones y metodos para usar anticuerpos bispecificos para unirse al complemento y a un antigeno objetivo.
MX2023011339A (es) Anticuerpos anti-tau y usos de estos.
WO2021226321A3 (en) Anti-tumor associated antigen antibodies and uses thereof
PE20251275A1 (es) Agentes aglutinantes 5t4 y usos de los mismos
AR127273A1 (es) Anticuerpos biespecíficos que se unen específicamente a cd47 y her2 y usos de los mismos
EA202092122A1 (ru) Антитела против tip-1 и их применения
MX2023009211A (es) Anticuerpos biespecificos con pares de carga y usos de los mismos.
AR131528A1 (es) Anticuerpos anti-b7h3 y métodos de uso
MX2025010155A (es) Composiciones que comprenden un anticuerpo biespecifico para gprc5d/cd3